Ketorolac Tromethamine Patent Expiration
Ketorolac Tromethamine was first introduced by Roche Palo Alto Llc
Ketorolac Tromethamine Patents
Given below is the list of patents protecting Ketorolac Tromethamine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Acuvail | US7842714 | Ketorolac tromethamine compositions for treating ocular pain | Aug 15, 2029 | Abbvie |
| Acuvail | US8512717 | Compositions for delivery of therapeutics into the eyes and methods for making and using same | Mar 07, 2028 | Abbvie |
| Acuvail | US9192571 | Ketorolac tromethamine compositions for treating or preventing ocular pain | Mar 07, 2028 | Abbvie |
| Acular Ls |
US8008338 (Pediatric) | Ketorolac tromethamine compositions for treating or preventing ocular pain | Nov 24, 2027 | Abbvie |
| Acular Ls | US8008338 | Ketorolac tromethamine compositions for treating or preventing ocular pain | May 24, 2027 | Abbvie |
| Acular Ls |
US8207215 (Pediatric) | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov 28, 2024
(Expired) | Abbvie |
| Acular Ls |
US8377982 (Pediatric) | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov 28, 2024
(Expired) | Abbvie |
| Acular Ls |
US8541463 (Pediatric) | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov 28, 2024
(Expired) | Abbvie |
| Acuvail | US8992952 | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug 05, 2024
(Expired) | Abbvie |
| Acular Ls | US8207215 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May 28, 2024
(Expired) | Abbvie |
| Acular Ls | US8377982 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May 28, 2024
(Expired) | Abbvie |
| Acular Ls | US8541463 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May 28, 2024
(Expired) | Abbvie |
| Acular Ls | US8648107 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May 28, 2024
(Expired) | Abbvie |
| Acular Ls | US8906950 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May 28, 2024
(Expired) | Abbvie |
| Acular Ls | US8946281 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May 28, 2024
(Expired) | Abbvie |
| Acular Ls | US9216127 | Burial vault and method for customizing a burial vault |
May 28, 2024
(Expired) | Abbvie |
| Acular Ls | US9216167 | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May 28, 2024
(Expired) | Abbvie |
| Sprix | US6333044 | Therapeutic compositions for intranasal administration which include KETOROLAC® |
Dec 25, 2018
(Expired) | Cosette |
| Sprix | US7476689 | Therapeutic compositions for intranasal administration which include KETOROLAC |
Oct 11, 2012
(Expired) | Cosette |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Ketorolac Tromethamine's patents.
Latest Legal Activities on Ketorolac Tromethamine's Patents
Given below is the list recent legal activities going on the following patents of Ketorolac Tromethamine.
| Activity | Date | Patent Number |
|---|---|---|
| ||
| Expire Patent Critical
| 10 Feb, 2017 | US7476689 |
| Correspondence Address Change Critical
| 27 Oct, 2010 | US7476689 |
| Recordation of Patent Grant Mailed Critical
| 13 Jan, 2009 | US7476689 |
| Patent Issue Date Used in PTA Calculation Critical
| 13 Jan, 2009 | US7476689 |
| Issue Notification Mailed Critical
| 22 Dec, 2008 | US7476689 |
| Dispatch to FDC | 15 Dec, 2008 | US7476689 |
| Printer Rush- No mailing | 05 Dec, 2008 | US7476689 |
| Pubs Case Remand to TC Critical
| 13 Nov, 2008 | US7476689 |
| Printer Rush- No mailing | 05 Nov, 2008 | US7476689 |
| Pubs Case Remand to TC Critical
| 29 Sep, 2008 | US7476689 |
Ketorolac Tromethamine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ketorolac Tromethamine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy | The Second People's Hospital of Huai'an | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1, PHASE2 |
| Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy | Neumentum, Inc. | NA |
SUSPENDED
(Apr 1, 2026)
| PHASE3 |
| The Effect of Anti-inflammatory Cryoagent on the Level of Postoperative Pain in Patients With Symptomatic Irreversible Pulpitis and Apical Periodontitis. | Ain Shams University | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE2 |